Editas Medicine (EDIT) Gets a Hold from Oppenheimer
Oppenheimer analyst Jay Olson maintained a Hold rating on Editas Medicine (EDIT – Research Report) today and set a price target of ...
Editas Medicine (EDIT) Gets a Buy from Truist Financial
In a report released today, Joon Lee from Truist Financial maintained a Buy rating on Editas Medicine (EDIT – Research Report). The ...
Zacks.com on MSN13h
EDIT Seeks Partner for Reni-Cel Developmental Program, Stock Down
Shares of Editas Medicine EDIT plunged 12.5% on Tuesday after announcing that it is seeking a global partner to advance its ...
precisionmedicineonline14h
Editas Seeking Partner or Licensing Deal for Lead Sickle Cell, TDT Gene-Editing Treatment Candidate
The strategic shift will allow the firm to focus on advancing a newly announced in vivo gene-editing therapy candidate that's in preclinical development.
STAT22h
‘Switchable’ CAR-T startup raises $112 million
AvenCell Therapeutics announced that it raised $115 million in a Series B round. The company is developing CAR-T therapies ...